Yes

Keratolytic Agent

Topical treatment of benign growths including external genital and perianal warts, papillomas, fibroids; compound benzoin tincture generally is used as the medium for topical application

X

Not to be used on birthmarks, moles, or warts with hair growth; cervical, urethral, oral warts; not to be used by diabetic patient or patient with poor circulation; pregnant women

Use of large amounts of drug should be avoided; avoid contact with the eyes as it can cause severe corneal damage; do not apply to moles, birthmarks, or unusual warts; to be applied by a physician only; for external use only; 25% solution should not be applied to or near mucous membranes

1% to 10%:

Dermatologic: Pruritus

Gastrointestinal: Nausea, vomiting, abdominal pain, diarrhea

<1%: Confusion, lethargy, hallucinations, leukopenia, thrombocytopenia, hepatotoxicity, peripheral neuropathy, renal failure

No data reported

Directly affects epithelial cell metabolism by arresting mitosis through binding to a protein subunit of spindle microtubules (tubulin)

Topical:

Condylomata acuminatum: 25% solution is applied daily; use a 10% solution when applied to or near mucous membranes

Verrucae: 25% solution is applied 3-5 times/day directly to the wart

No information available to require special precautions

No effects or complications reported

Cover with occlusive dressing to prevent contact with unaffected skin. Wash off medication as instructed by professional who applied the treatment. Pregnancy/breast-feeding precautions: Inform prescriber if you are pregnant. Do not get pregnant during or for 1 month following therapy. Consult prescriber for instruction on appropriate barrier contraceptive measures. This drug may cause severe fetal defects. Do not breast-feed.

Shake well before using; solution should be washed off within 1-4 hours for genital and perianal warts and within 1-2 hours for accessible meatal warts; use protective occlusive dressing around warts to prevent contact with unaffected skin

Liquid, topical: 25% in benzoin (5 mL, 7.5 mL, 30 mL)

"1993 Sexually Transmitted Diseases Treatment Guidelines," MMWR Morb Mortal Wkly Rep, 1993, 42(RR-14):1-102.

Goldfarb MT, Gupta AK, Gupta MA, et al, "Office Therapy for Human Papillomavirus Infection in Nongenital Sites," Dermatol Clin, 1991, 9(2):287-96.